• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Legend Biotech Corp ADR (NQ: LEGN )

    46.71 UNCHANGED
    Streaming Delayed Price Updated: 4:00 PM EDT, Jul 9, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 81
    Open 46.71
    Bid (Size) 45.92 (2)
    Ask (Size) 47.96 (1)
    Prev. Close 46.71
    Today's Range 46.71 - 46.71
    52wk Range 38.60 - 77.32
    Shares Outstanding 308,456,852
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Legend Biotech to Host Investor Conference Call on Second Quarter 2024 Results
    From Legend Biotech USA Inc.
    Via GlobeNewswire
    Johnson & Johnson's Cell Therapy Carvykti Shows Better Survival Rate In Pretreated Blood Cancer Patients
    Johnson & Johnson announced Phase 3 CARTITUDE-4 study results showing Carvykti significantly improves overall survival in relapsed or lenalidomide-refractory multiple myeloma after one prior line of... 
    Via Benzinga

    Performance

    YTD
    -20.96%
    -20.96%
    1 Month
    +2.57%
    +2.57%
    3 Month
    -17.12%
    -17.12%
    6 Month
    -20.99%
    -20.99%
    1 Year
    -34.26%
    -34.26%

    More News

    Read More
    Legend Biotech Announces Positive Overall Survival Results of Landmark Phase 3 CARTITUDE-4 Trial in Multiple Myeloma
    From Legend Biotech USA Inc.
    Via GlobeNewswire
    Assessing Legend Biotech: Insights From 15 Financial Analysts
    Via Benzinga
    Unveiling 18 Analyst Insights On Legend Biotech
    Via Benzinga
    Legend Biotech Stock: A Deep Dive Into Analyst Perspectives (14 Ratings)
    Via Benzinga
    Legend Biotech's Cancer Drug, 'The Most Attractive Product,' Set For Growth: Analyst
    Via Benzinga
    Novavax And Agios Pharmaceuticals Were Among The 10 Biggest Mid-Cap Gainers Last Week (June 1-June 7): Are These In Your Portfolio?
    Via Benzinga
    Legend Biotech Shares Data on the Earliest Use to Date of CARVYKTI® in the Treatment of Multiple Myeloma and Important Subgroup Analyses at ASCO and EHA
    From Legend Biotech
    Via Business Wire
    Analyst Ratings For Legend Biotech
    Via Benzinga
    Unveiling 9 Analyst Insights On Legend Biotech
    Via Benzinga
    Legend Biotech to Participate in the Jefferies Global Healthcare Conference
    From Legend Biotech Corporation
    Via Business Wire
    Legend Biotech to Highlight Leadership in CAR-T Cell Therapy for Patients with Multiple Myeloma at ASCO and EHA
    From Legend Biotech Corporation
    Via Business Wire
    Amid Biotech Pitfalls, ImmunityBio Has Outperformed NVDA In The Last 3 Months
    Via Talk Markets
    LEGN Stock Earnings: Legend Biotech Beats EPS, Misses Revenue for Q1 2024
    Via InvestorPlace
    Legend Biotech Reports First Quarter 2024 Results and Recent Highlights
    From Legend Biotech Corporation
    Via Business Wire
    CARVYKTI® (ciltacabtagene autoleucel) Approved by the European Commission for Second-line Treatment of Patients with Relapsed and Refractory Multiple Myeloma
    From Legend Biotech Corporation
    Via Business Wire
    FDA Mandates "Boxed Warning" For Bristol Myers, Johnson & Johnson CAR-T-Based Blood Cancer Therapies
    Via Benzinga
    Exposures Product Safety
    Legend Biotech to Host Investor Conference Call on First Quarter 2024 Results
    From Legend Biotech Corporation
    Via Business Wire
    Johnson & Johnson's Carvykti Stands Ahead Of Bristol Myers' Rival Blood Cancer Therapy With FDA Approval For Wider Population
    Via Benzinga
    Exposures Product Safety
    Legend Biotech’s CARVYKTI® (ciltacabtagene autoleucel) Becomes the First and Only BCMA-Targeted CAR-T Cell Therapy Approved by the FDA for Second-Line Treatment of Multiple Myeloma
    From Legend Biotech Corporation
    Via Business Wire
    GenScript Losses Shrink On Strong Growth For Cancer Cell Therapy
    Via Benzinga
    Legend Biotech Announces Publication of Inaugural Environmental, Social and Governance (ESG) Report
    From Legend Biotech Corporation
    Via Business Wire
    FDA Adcomm Favors Expanded Use Of Johnson & Johnson, Bristol Myers' CAR-T Therapies For Type Of Blood Cancer
    Via Benzinga
    Exposures Product Safety
    CARVYKTI® (ciltacabtagene autoleucel) Receives Recommendation from the U.S. FDA Oncologic Drugs Advisory Committee for Earlier Treatment of Patients with Relapsed/Refractory Multiple Myeloma
    From Legend Biotech Corporation
    Via Business Wire
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.